

Gesamtbericht

19. Durchgang des Rundversuches **Gerinnung und Ger.-Faktoren**

Wien, am 15.09.2022

Sehr geehrte Frau Kollegin, sehr geehrter Herr Kollege,

bei dem 19. Durchgang des Rundversuches Gerinnung und Ger.-Faktoren wurde die Probenverteilung am 22.08.2022 gestartet. Die Rücksendefrist endete am 10.09.2022. Die statistische Berechnung erfolgte am 15.09.2022.

Folgende Proben wurden ausgesandt:

Probenoption	Bezeichnung	Hersteller
A	Kontrollplasma N	Siemens
B	Kontrollplasma P	Siemens

Erläuterungen zu den Tabellenspalten

Probe	jeweilige Probe
AnzE	Anzahl der eingelangten Ergebnisse

Metrische Resultate

Kollektiv	Methodenkollektiv dem die von Teilnehmern übermittelten Ergebnisse zugeordnet wurden
*	Kollektiv ohne Bewertung (da die Anzahl der eingegangenen Teilnehmerergebnisse weniger als 6 oder Anzahl der Ergebnisse innerhalb der Akzeptanzgrenzen weniger als 5 ist); die Angabe der Ergebnisse hat nur informativen Charakter
Zielwert	der der Probe zugewiesene Wert in diesem Rundversuch [das für die Bestimmung des Zielwerts verwendete Ermittlungsverfahren] [a] Referenzwert [b] Konsenswert
%-Abw	tolerierte Abweichung vom Zielwert in %
AGrenzen	Akzeptanzintervall
Innerhalb	Anzahl und Anteil der Ergebnisse, die innerhalb des Akzeptanzintervalls liegen
Außerhalb	Anzahl und Anteil der Ergebnisse, die außerhalb des Akzeptanzintervalls liegen
MW	Mittelwert
Median	Median
SD	Standardabweichung
VK	Variationskoeffizient

Nominale Resultate

Angabe	von Teilnehmern übermittelte Angaben
Referenz	das der Probe zugewiesene Ergebnis in diesem Rundversuch [das für die Bestimmung der Referenz verwendete Ermittlungsverfahren] [a] Referenzwert [b] Konsenswert
Anteil	Anzahl und Anteil der Ergebnisse die der Referenz entsprechen



Es wurden folgende Ergebnisse erzielt:

TPZ %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
STA-NeoPTimal/rabbit	A	29	90.1 [b]	20	[72.1...108.1]	29 (100%)	0 (0%)	90.1	90.0	2.9	3.27
	B	29	35.0 [b]	20	[28.0...42.0]	29 (100%)	0 (0%)	35.0	35.0	1.4	3.86
alle	A	219	91.3 [b]	20	[73.1...109.6]	212 (97%)	7 (3%)	91.3	91.5	6.3	6.94
	B	219	35.5 [b]	20	[28.4...42.6]	195 (89%)	24 (11%)	35.5	35.0	3.7	10.29
Cube-S/*****	A	2						115.3*	115.3*	*	*
	B	2						40.4*	40.4*	*	*
Innovin-Multi-Kal./recomb.	A	27	90.6 [b]	20	[72.4...108.7]	27 (100%)	0 (0%)	90.6	91.0	3.2	3.48
	B	27	34.4 [b]	20	[27.5...41.3]	27 (100%)	0 (0%)	34.4	34.8	1.4	4.18
Innovin/recomb.	A	12	91.3 [b]	20	[73.0...109.5]	12 (100%)	0 (0%)	91.3	91.5	2.9	3.19
	B	12	34.0 [b]	20	[27.2...40.8]	12 (100%)	0 (0%)	34.0	34.5	1.6	4.83
Neoplastine	A	7	89.2 [b]	20	[71.3...107.0]	6 (86%)	1 (14%)	89.2	90.0	9.2	10.37
	B	7	36.4 [b]	20	[29.1...43.7]	6 (86%)	1 (14%)	36.4	38.0	4.6	12.70
PT Rec/human	A	4						92.4*	92.5*	2.0*	2.16*
	B	4						31.0*	30.9*	1.4*	4.67*
PT Screen/human	A	7	91.6 [b]	20	[73.3...110.0]	7 (100%)	0 (0%)	91.6	89.9	8.7	9.48
	B	7	41.0 [b]	20	[32.8...49.2]	7 (100%)	0 (0%)	41.0	40.7	2.6	6.44
PT-Dimex jr./bovine+	A	1						111.0*	111.0*	*	*
	B	1						66.0*	66.0*	*	*
ReadiPlasTin/recomb.	A	21	96.2 [b]	20	[77.0...115.5]	21 (100%)	0 (0%)	96.2	97.5	3.6	3.73
	B	21	35.6 [b]	20	[28.5...42.7]	21 (100%)	0 (0%)	35.6	36.0	1.8	5.10
RecombiPlasTin 2G/recomb.	A	26	96.9 [b]	20	[77.5...116.3]	26 (100%)	0 (0%)	96.9	96.5	5.2	5.41
	B	26	34.9 [b]	20	[27.9...41.9]	26 (100%)	0 (0%)	34.9	35.0	1.8	5.02
STA HEPATO-PREST / rabbit	A	7	89.3 [b]	20	[71.5...107.2]	7 (100%)	0 (0%)	89.3	91.0	6.4	7.14
	B	7	31.5 [b]	20	[25.2...37.8]	7 (100%)	0 (0%)	31.5	31.0	1.8	5.62
Smart 700/*****	A	1						79.9*	79.9*	*	*
	B	1						36.5*	36.5*	*	*
Smart 700/340)*****	A	1						81.0*	81.0*	*	*
	B	1						67.3*	67.3*	*	*
Technoclot PT Owren	A	12	78.5 [b]	20	[62.8...94.2]	12 (100%)	0 (0%)	78.5	76.7	8.2	10.45
	B	12	34.7 [b]	20	[27.8...41.7]	11 (92%)	1 (8%)	34.7	33.8	5.2	14.85
Thromborel S-Multi-Kal./human	A	31	90.8 [b]	20	[72.7...109.0]	31 (100%)	0 (0%)	90.8	93.6	7.3	8.06
	B	31	38.9 [b]	20	[31.1...46.7]	29 (94%)	2 (6%)	38.9	40.0	4.8	12.35
Thromborel S/human	A	31	89.5 [b]	20	[71.6...107.4]	30 (97%)	1 (3%)	89.5	88.4	8.5	9.50
	B	31	37.4 [b]	20	[29.9...44.9]	29 (94%)	2 (6%)	37.4	38.0	4.6	12.43

S-Kurven aller Proben



Youden-Plots aller Probenpaare





INR


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	222	1.05 [b]	20	[0.84...1.26]	221 (100%)	1 (0%)	1.05	1.05	0.05	5.09
	B	222	2.02 [b]	20	[1.62...2.42]	216 (97%)	6 (3%)	2.02	2.01	0.21	10.33
bovine	A	6	1.00 [b]	20	[0.80...1.19]	6 (100%)	0 (0%)	0.99	0.96	0.16	16.45
	B	6						1.66*	1.65*	0.59*	35.46*
human	A	73	1.07 [b]	20	[0.85...1.28]	73 (100%)	0 (0%)	1.07	1.08	0.06	5.16
	B	73	1.95 [b]	20	[1.56...2.34]	71 (97%)	2 (3%)	1.95	1.93	0.21	10.73
rabbit	A	56	1.09 [b]	20	[0.87...1.30]	55 (98%)	1 (2%)	1.09	1.08	0.05	4.43
	B	56	2.08 [b]	20	[1.67...2.50]	53 (95%)	3 (5%)	2.08	2.13	0.18	8.43
recombinant	A	87	1.02 [b]	20	[0.82...1.23]	87 (100%)	0 (0%)	1.02	1.03	0.03	2.98
	B	87	2.05 [b]	20	[1.64...2.46]	87 (100%)	0 (0%)	2.05	2.02	0.16	7.78

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Partielle Thromboplastinzeit (aPTT) sec


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
STA CEPHASCREEN	A	25	29 [b]	20	[23...35]	25 (100%)	0 (0%)	29	29	2	5.63
	B	25	53 [b]	20	[42...63]	25 (100%)	0 (0%)	53	52	2	3.84
alle	A	197	28 [b]	20	[23...34]	191 (97%)	6 (3%)	28	28	3	10.46
	B	197	62 [b]	20	[50...74]	123 (62%)	74 (38%)	62	58	11	18.13
Actin	A	5						25*	25*	1*	4.85*
	B	5						97*	97*	4*	4.59*
Actin FS	A	46	25 [b]	20	[20...30]	46 (100%)	0 (0%)	25	25	1	4.00
	B	46	53 [b]	20	[42...63]	44 (96%)	2 (4%)	53	54	6	12.14
Actin FSL	A	11	26 [b]	20	[21...31]	11 (100%)	0 (0%)	26	26	1	3.64
	B	11	70 [b]	20	[56...84]	11 (100%)	0 (0%)	70	69	3	4.82
CK PREST	A	3						31*	31*	1*	2.56*
	B	3						64*	64*	8*	13.00*
Cephalin LT	A	1						70*	70*	*	*
	B	1						32*	32*	*	*
Pathromtin SL	A	34	31 [b]	20	[25...37]	34 (100%)	0 (0%)	31	31	1	3.72
	B	34	95 [b]	20	[76...114]	34 (100%)	0 (0%)	95	95	5	5.64
STA PTT Automate	A	8	33 [b]	20	[27...40]	8 (100%)	0 (0%)	33	33	1	2.43
	B	8	70 [b]	20	[56...84]	8 (100%)	0 (0%)	70	70	2	3.28
SynthASIL	A	45	28 [b]	20	[23...34]	45 (100%)	0 (0%)	28	28	1	2.56
	B	45	55 [b]	20	[44...66]	45 (100%)	0 (0%)	55	56	4	6.71
aPTT MedS	A	12	30 [b]	20	[24...36]	12 (100%)	0 (0%)	30	30	1	3.19
	B	12	94 [b]	20	[75...113]	12 (100%)	0 (0%)	94	95	4	3.84
andere	A	7	33 [b]	20	[27...40]	7 (100%)	0 (0%)	33	34	3	8.74
	B	7	67 [b]	20	[54...81]	7 (100%)	0 (0%)	67	67	4	5.29

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Thrombinzeit sec


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	100	19 [b]	20	[15...23]	100 (100%)	0 (0%)	19	19	1	7.00
	B	100	25 [b]	20	[20...29]	93 (93%)	7 (7%)	25	25	3	13.10
IL	A	25	18 [b]	20	[15...22]	25 (100%)	0 (0%)	18	18	1	4.66
	B	25	26 [b]	20	[21...32]	25 (100%)	0 (0%)	26	26	1	4.97
Siemens	A	38	19 [b]	20	[16...23]	38 (100%)	0 (0%)	19	20	1	6.59
	B	38	24 [b]	20	[20...29]	38 (100%)	0 (0%)	24	25	2	7.57
Stago	A	23	18 [b]	20	[14...22]	23 (100%)	0 (0%)	18	18	1	3.50
	B	23	21 [b]	20	[17...25]	23 (100%)	0 (0%)	21	21	1	4.52
Thr < 1,0/BC-Thrombin	A	12	20 [b]	20	[16...25]	12 (100%)	0 (0%)	20	20	1	7.32
	B	12	29 [b]	20	[23...35]	11 (92%)	1 (8%)	29	29	3	10.96
Thr < 1,0/Roche	A	1						22*	22*	*	*
	B	1						34*	34*	*	*
Thr < 1,0/Thromboclotin	A	1						17*	17*	*	*
	B	1						14*	14*	*	*

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Fibrinogen mg/dl


Split: Reagens

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	170	243 [b]	20	[194...291]	169 (99%)	1 (1%)	243	243	14	5.81
	B	170	81 [b]	20	[65...97]	158 (93%)	12 (7%)	81	81	6	7.79
IL	A	44	247 [b]	20	[198...297]	44 (100%)	0 (0%)	247	247	12	4.71
	B	44	82 [b]	20	[66...98]	42 (95%)	2 (5%)	82	82	4	4.78
Roche	A	9	239 [b]	20	[191...286]	8 (89%)	1 (11%)	239	243	19	7.92
	B	9	76 [b]	20	[61...91]	8 (89%)	1 (11%)	76	77	7	9.61
Siemens/D	A	59	234 [b]	20	[187...281]	59 (100%)	0 (0%)	234	234	15	6.60
	B	59	79 [b]	20	[63...94]	54 (92%)	5 (8%)	79	79	6	8.09
Siemens/DB	A	21	245 [b]	20	[196...294]	21 (100%)	0 (0%)	245	244	10	4.14
	B	21	93 [b]	20	[75...112]	20 (95%)	1 (5%)	93	95	8	8.86
Stago	A	35	249 [b]	20	[199...299]	35 (100%)	0 (0%)	249	247	11	4.32
	B	35	79 [b]	20	[64...95]	35 (100%)	0 (0%)	79	79	3	3.55
Technoclone	A	2						271*	271*	*	*
	B	2						88*	88*	*	*

S-Kurven aller Proben



Youden-Plots aller Probenpaare




Fibrinogen derived mg/dl


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	4						204*	195*	22*	10.85*
	B	4						146*	150*	71*	48.72*
Innovin/recomb.	A	2						190*	190*	*	*
	B	2						190*	190*	*	*
RecombiPlasTin 2G/recomb.	A	1						242*	242*	*	*
	B	1						92*	92*	*	*
Thromborel S-Multi-Kal./human	A	1						200*	200*	*	*
	B	1						110*	110*	*	*

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Antithrombin III %


Split: Reagens

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	135	93 [b]	20	[74...111]	134 (99%)	1 (1%)	93	92	4	4.75
	B	135	31 [b]	35	[20...42]	132 (98%)	3 (2%)	31	30	3	10.81
Berichrom/Siemens	A	39	90 [b]	20	[72...108]	39 (100%)	0 (0%)	90	91	4	4.15
	B	39	30 [b]	35	[20...41]	39 (100%)	0 (0%)	30	30	3	8.64
IL	A	37	93 [b]	20	[75...112]	37 (100%)	0 (0%)	93	93	4	4.08
	B	37	29 [b]	35	[19...39]	36 (97%)	1 (3%)	29	29	4	12.26
Innovance/Siemens	A	23	93 [b]	20	[75...112]	23 (100%)	0 (0%)	93	94	4	4.46
	B	23	31 [b]	35	[20...42]	23 (100%)	0 (0%)	31	31	2	6.22
Roche	A	4						90*	91*	2*	2.15*
	B	4						29*	29*	0*	0.00*
Roche/BM	A	1						34*	34*	*	*
	B	1						96*	96*	*	*
Stago	A	29	95 [b]	20	[76...114]	29 (100%)	0 (0%)	95	95	4	3.68
	B	29	34 [b]	35	[22...45]	29 (100%)	0 (0%)	34	34	3	9.41
Technoclone	A	2						99*	99*	*	*
	B	2						40*	40*	*	*

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Faktor II %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	17	93 [b]	30	[65...121]	17 (100%)	0 (0%)	93	92	8	8.13
	B	17	32 [b]	30	[23...42]	17 (100%)	0 (0%)	32	32	4	12.09

S-Kurven aller Proben



Youden-Plots aller Probenpaare




Faktor V %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	18	82 [b]	30	[58...107]	18 (100%)	0 (0%)	82	81	8	9.11
	B	18	27 [b]	30	[19...35]	18 (100%)	0 (0%)	27	27	3	10.60

S-Kurven aller Proben




● Messwert ◆ Mittelwert & Std.-Abw.
— · Mittelwert nach Q-Hampel aller Kollektive (Methoden)



● Messwert ◆ Mittelwert & Std.-Abw.
— · Mittelwert nach Q-Hampel aller Kollektive (Methoden)

Youden-Plots aller Probenpaare





Faktor VII %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	18	91 [b]	30	[64...118]	18 (100%)	0 (0%)	91	91	10	11.02
	B	18	33 [b]	30	[23...42]	18 (100%)	0 (0%)	33	32	3	9.32

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Faktor X %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	17	88 [b]	30	[62...115]	17 (100%)	0 (0%)	88	89	7	8.38
	B	17	30 [b]	30	[21...39]	17 (100%)	0 (0%)	30	30	4	12.88

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Faktor VIII %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	28	93 [b]	30	[65...120]	26 (93%)	2 (7%)	93	93	10	11.05
	B	28	28 [b]	30	[20...37]	26 (93%)	2 (7%)	28	28	4	15.29

S-Kurven aller Proben



Youden-Plots aller Probenpaare




Faktor IX %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	21	93 [b]	30	[65...120]	19 (90%)	2 (10%)	93	93	9	10.08
	B	21	29 [b]	30	[20...38]	19 (90%)	2 (10%)	29	29	5	15.94

S-Kurven aller Proben




● Messwert ◆ Mittelwert & Std.-Abw.
- - Mittelwert nach Q-Hampel aller Kollektive (Methoden)



● Messwert ◆ Mittelwert & Std.-Abw.
- - Mittelwert nach Q-Hampel aller Kollektive (Methoden)

Youden-Plots aller Probenpaare





Faktor XI %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	19	97 [b]	30	[68...126]	19 (100%)	0 (0%)	97	96	10	9.92
	B	19	30 [b]	30	[21...39]	19 (100%)	0 (0%)	30	29	3	9.14

S-Kurven aller Proben



Youden-Plots aller Probenpaare





Faktor XII %


Split: Methode

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	17	108 [b]	30	[76...141]	17 (100%)	0 (0%)	108	109	9	8.13
	B	17	35 [b]	30	[25...46]	16 (94%)	1 (6%)	35	35	5	14.73

S-Kurven aller Proben



Youden-Plots aller Probenpaare




Faktor XIII %


Split: Reagens

Kollektiv	Probe	AnzE	Zielwert	%-Abw	AGrenzen	Innerhalb	Außerhalb	MW	Median	SD	VK %
alle	A	26	85 [b]	30	[59...110]	26 (100%)	0 (0%)	85	85	8	9.10
	B	26	29 [b]	30	[20...38]	25 (96%)	1 (4%)	29	30	3	11.87

S-Kurven aller Proben



Youden-Plots aller Probenpaare



Vergleichbarkeitsklassen (Kollektive)

TPZ %

Nummer	Kollektiv	Attribut	Ausprägung
1	STA-NeoPTimal/rabbit	Methode	STA PTF/rabbit STA-NeoPTimal/rabbit
2	Cube-S/*****	Methode	Cube-S/*****
3	Innovin-Multi-Kal./recomb.	Methode	Innovin-Multi-Kal./recomb.
4	Innovin/recomb.	Methode	Innovin/recomb.
5	Neoplastine	Methode	Neopl.-Plus/rabbit Neoplastine CI +/-rabbit STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit
6	PT Rec/human	Methode	PT Rec/human
7	PT Screen/human	Methode	PT Screen/human
8	PT-Dimex jr./bovine+	Methode	PT-Dimex jr./bovine+
9	ReadiPlasTin/recomb.	Methode	ReadiPlasTin/recomb.
10	RecombiPlasTin 2G/recomb.	Methode	RecombiPlasTin 2G/recomb.
11	STA HEPATO-PREST / rabbit	Methode	STA HEPATO-PREST / rabbit
12	Smart 700/*****	Methode	Smart 700/*****
13	Smart 700/340/*****	Methode	Smart 700/340/*****
14	Technoclot PT Owren	Methode	Technoclot PT Owren autom./rabbit Technoclot PT Owren man.-KB/rabbit Technoclot PT Owren man.-P/rabbit
15	Thromborel S-Multi-Kal./human	Methode	Thromborel S-Multi-Kal./human
16	Thromborel S/human	Methode	Thromborel S/human

INR

Nummer	Kollektiv	Attribut	Ausprägung
1	bovine	Methode	Cube-S/***** PT-Dimex jr./bovine+ Smart 700/***** Smart 700/340/*****
2	human	Methode	PT Rec/human PT Screen/human Thromborel S-Multi-Kal./human Thromborel S/human
3	rabbit	Methode	Neopl.-Plus/rabbit Neoplastine CI +/-rabbit STA HEPATO-PREST / rabbit STA NEOPLASTIN CI +/-rabbit STA PTF/rabbit STA-NeoPTimal/rabbit Technoclot PT Owren autom./rabbit Technoclot PT Owren man.-KB/rabbit Technoclot PT Owren man.-P/rabbit Technoplastin HIS/rabbit
4	recombinant	Methode	Innovin-Multi-Kal./recomb. Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN R/recomb.

Partielle Thromboplastinzeit (aPTT) sec

Nummer	Kollektiv	Attribut	Ausprägung
1	STA CEPHASCREEN	Methode	aPTT SP SIRON LS STA CEPHASCREEN
2	Actin	Methode	Actin
3	Actin FS	Methode	Actin FS
4	Actin FSL	Methode	Actin FSL
5	CK PREST	Methode	CK PREST
6	Cephalin LT	Methode	Cephalin LT
7	Pathromtin SL	Methode	Pathromtin SL
8	STA PTT Automate	Methode	STA PTT Automate
9	SynthASIL	Methode	SynthASIL
10	aPTT MedS	Methode	aPTT MedS aPTT Screen Dapttin
11	andere	Methode	PTT Automate

			STA APTT (Ceph.-akt) STA CK PREST
--	--	--	--------------------------------------

Thrombinzeit sec

Nummer	Kollektiv	Attribut	Ausprägung
1	IL	Methode	Thr < 2,0/Instr. Lab. Thr > 3,0/Instr. Lab.
2	Siemens	Methode	Thr < 0,51/Test-Thr. Siemens Thr < 1,0/Test-Thr. Siemens Thr < 2,0/Test-Thr. Siemens Thr > 2,0/Test-Thr. Siemens
3	Stago	Methode	STA- Thrombin Thr < 1,0/Stago Thr < 2,0/Stago Thr < 2,0/TC
4	Thr < 1,0/BC-Thrombin	Methode	Thr < 2,0/Instr. Lab. * Thr < 1,0/BC-Thrombin
5	Thr < 1,0/Roche	Methode	Thr < 1,0/Roche
6	Thr < 1,0/Thromboclotin	Methode	Thr < 1,0/Thromboclotin

Fibrinogen mg/dl

Nummer	Kollektiv	Attribut	Ausprägung
1	IL	Reagens	Instr. Lab. Instr. Lab./TOP
2	Roche	Reagens	Roche Roche/BM
3	Siemens/D	Reagens	Siemens/D
4	Siemens/DB	Reagens	Siemens/DB
5	Stago	Reagens	Stago
6	Technoclone	Reagens	Technoclone

Fibrinogen derived mg/dl

Nummer	Kollektiv	Attribut	Ausprägung
1	Innovin/recomb.	Methode	Innovin/recomb.
2	RecombiPlasTin 2G/recomb.	Methode	RecombiPlasTin 2G/recomb.
3	Thromborel S-Multi-Kal./human	Methode	Thromborel S-Multi-Kal./human

Antithrombin III %

Nummer	Kollektiv	Attribut	Ausprägung
1	Berichrom/Siemens	Reagens	Berichrom/Siemens Siemens/DB
2	IL	Reagens	Instr. Lab. Instr. Lab./TOP
3	Innovance/Siemens	Reagens	Innovance/Siemens
4	Roche	Reagens	Roche
5	Roche/BM	Reagens	Roche/BM
6	Stago	Reagens	Stago
7	Technoclone	Reagens	Technoclone

Faktor II %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Faktor V %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Faktor VII %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Faktor X %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Innovin/recomb. ReadiPlasTin/recomb. RecombiPlasTin 2G/recomb. STA NEOPLASTIN CI +/-rabbit STA NEOPLASTIN R/recomb. Technoplastin HIS/rabbit Thromborel S/human

Faktor VIII %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Actin FS Chrom./Siemens Chrom.Substr. Kaolin Pathromtin SL SIRON LS STA CK PREST SynthASIL

Faktor IX %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Actin FS Chrom.Substr. Pathromtin SL SIRON LS STA CK PREST SynthASIL

Faktor XI %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Actin FS Pathromtin SL SIRON LS STA CK PREST SynthASIL

Faktor XII %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Methode	Actin FS Pathromtin SL SIRON LS STA CEPHASCREEN STA CK PREST SynthASIL

Faktor XIII %

Nummer	Kollektiv	Attribut	Ausprägung
1	alle	Reagens	Kamiya K-Assay Berichrom/Siemens Hexamat/MBL Instr. Lab. Siemens/DB Technochrom/TC

Mit besten Grüßen

Dr. Christoph Buchta, MBA
Technische Leitung

Prim. Univ. Doz. Dr. Alexander Haushofer
Versuchsleitung